Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 183

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Economic Implications of Evidence-Based Prescribing for Hypertension: Can Better Care Cost Less?

Fischer, Michael A., Avorn, Jerry·2004·JAMA

Abstract

CONTEXT: Deviation from evidence-based guidelines in hypertension treatment is common, but its economic impact has not been rigorously studied. Suboptimal prescribing patterns contribute to the high cost of medications for elderly patients as well as the difficulty in providing affordable prescription drug benefits for older Americans. OBJECTIVE: To calculate the potential savings from the perspective of health care payers that would result from increased adherence to evidence-based recommendations for managing hypertension in patients older than 65 years. DESIGN: Comparative analysis of medications prescribed vs potential regimens suggested by evidence-based guidelines tailored to each patient's medical history, with calculation of the costs of both the actual and the evidence-based regimens. SETTING AND PATIENTS: A total of 133,624 patients being treated for hypertension during 2001 who were enrolled in a large state pharmaceutical assistance program that provides prescription drug insurance for elderly persons. MAIN OUTCOME MEASURE: Cost difference between medications actually prescribed and regimens suggested by evidence-based guidelines. RESULTS: The patients studied filled more than 2.05 million prescriptions for antihypertensive medications in 2001, at an annual program cost of 48.5 million dollars (363 dollars per patient). We identified 815,316 prescriptions (40%) for which an alternative regimen appeared more appropriate according to evidence-based recommendations. Such changes would have reduced the costs to payers in 2001 by 11.6 million dollars (nearly a quarter of program spending on antihypertensive medications), as well as being more clinically appropriate overall. Replacement of calcium channel blockers resulted in the largest potential savings. Use of pricing limits similar to those in the Medicaid program would have resulted in even larger potential savings of 20.5 million dollars (42% of program costs). CONCLUSIONS: Adherence to evidence-based prescribing guidelines for hypertension could result in substantial savings in prescription costs for elderly patients with hypertension that would amount to savings of about 1.2 billion dollars nationally. Identification of similar areas in which prescribing can be improved will be critical for the affordability of prescription drug benefit programs.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1001/jama.291.15.1850

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Cited by

See all 183

Metadata

Authors
Fischer, M. A., & Avorn, J.
Venue
JAMA
Published
2004-04-21
Volume
291
Issue
15
Pages
1850
ISSN
  • 0002-9955 (ISSN-L)
  • 0098-7484
OpenAlex
W2021645358
Cited by
183
References
6
FWCI
9.71
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Economic Implications of Evidence-Based Prescribing for Hypertension: Can Better Care Cost Less? https://app.cochat.ai/papers/10.1001/jama.291.15.1850
The paper
Fischer, M. A., & Avorn, J. (2004). Economic Implications of Evidence-Based Prescribing for Hypertension: Can Better Care Cost Less? JAMA. https://doi.org/10.1001/jama.291.15.1850

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.